284 related articles for article (PubMed ID: 20571805)
1. [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Ophthalmologe; 2011 Mar; 108(3):244-51. PubMed ID: 20571805
[TBL] [Abstract][Full Text] [Related]
2. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
5. Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD.
Gutfleisch M; Heimes B; Schumacher M; Dietzel M; Lommatzsch A; Bird A; Pauleikhoff D
Eye (Lond); 2011 Sep; 25(9):1181-6. PubMed ID: 21701525
[TBL] [Abstract][Full Text] [Related]
6. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
[TBL] [Abstract][Full Text] [Related]
7. Anatomical and visual outcomes of ranibizumab injections in retinal pigment epithelium tears.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Sari ES
Arq Bras Oftalmol; 2015; 78(3):168-72. PubMed ID: 26222106
[TBL] [Abstract][Full Text] [Related]
8. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.
Baba T; Kitahashi M; Kubota-Taniai M; Oshitari T; Yamamoto S
Ophthalmologica; 2012; 228(2):102-9. PubMed ID: 22508168
[TBL] [Abstract][Full Text] [Related]
9. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
[TBL] [Abstract][Full Text] [Related]
10. [Anti-VEGF treatment for retinal angiomatous proliferation].
Wolf A; Kook D; Kreutzer T; Gandorfer A; Haritoglou C; Kampik A; Ulbig M
Ophthalmologe; 2008 Sep; 105(9):845-51. PubMed ID: 18607601
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome.
Kim JM; Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
Korean J Ophthalmol; 2017 Jun; 31(3):240-248. PubMed ID: 28471100
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration.
Giansanti F; Bacherini D; Giacomelli G; Virgili G; Finocchio L; Fiore T; Vannozzi L; Menchini U
Eur J Ophthalmol; 2014; 24(3):402-8. PubMed ID: 24242217
[TBL] [Abstract][Full Text] [Related]
13. Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.
Chan CK; Abraham P; Sarraf D; Nuthi AS; Lin SG; McCannel CA
Eye (Lond); 2015 Jan; 29(1):80-7. PubMed ID: 25277305
[TBL] [Abstract][Full Text] [Related]
14. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments.
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Zeimer M; Pauleikhoff D
Eye (Lond); 2009 Dec; 23(12):2163-8. PubMed ID: 19197318
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
Reche-Frutos J; Calvo-Gonzalez C; Pérez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
[TBL] [Abstract][Full Text] [Related]
16. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.
Chan CK; Abraham P; Meyer CH; Kokame GT; Kaiser PK; Rauser ME; Gross JG; Nuthi AS; Lin SG; Daher NS
Retina; 2010 Feb; 30(2):203-11. PubMed ID: 19952998
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.
Lai TY; Chan WM; Liu DT; Lam DS
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1877-80. PubMed ID: 17901972
[TBL] [Abstract][Full Text] [Related]
18. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
Engelbert M; Zweifel SA; Freund KB
Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
[TBL] [Abstract][Full Text] [Related]
19. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]